US 11718616
JAK kinase inhibitor compounds for treatment of respiratory disease
granted A61KA61K31/416A61K31/437
Quick answer
US patent 11718616 (JAK kinase inhibitor compounds for treatment of respiratory disease) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/416, A61K31/437, A61P, A61P11/00